Goldie Kurtz, MD, reports on the radiotherapy (Gamma Knife) program at Penn Medicine, which saw a 30% growth between 2014 and 2016. At Penn, Gamma Knife was an early instance of personalized medicine, a reflection of the individualized treatment plans particular to stereotactic radiosurgery and increasingly, to the treatment of specific tumor types. Dr. Kurtz reviews this aspect in her discussion, as well as the evolution of radiation therapy and the prognostic scoring criteria for brain metastases, the distinctions between whole brain radiotherapy and stereotactic radiosurgery and the potential benefits of surveillance for patients prior to metastatic disease.
Related Links:
Related Videos
